Repaglinide re-branded

Daiichi Sankyo has acquired the sales and marketing rights for repaglinide in the UK. Repaglinide will be launched using the brand name Prandin. The existing brand of repaglinide, NovoNorm, will remain available for the next few months. Next year, Novonorm will be discontinued and repaglinide will only be marketed as Prandin.

The licence for Prandin is identical to that for Novonorm. Both products are indicated for the treatment of type 2 diabetes with hyperglycaemia uncontrolled by diet, weight reduction and exercise. They are also indicated in combination with metformin in type 2 diabetes not satisfactorily controlled on metformin alone.

The recommended starting dose is 0.5mg, followed by dose titration at one- to two-weekly intervals according to response.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more